BASEL, Switzerland, Nov. 12, 2026 (GLOBE NEWSWIRE) — Windward Bio Group AG (“Windward”) (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, today announced the pricing of its initial public offering of 10,294,117 common shares at a public offering price of $17.00 per share. In addition, Windward has granted the underwriters a 30-day option to purchase up to an additional 1,544,117 common shares at the initial public offering price, less the underwriting discounts and commissions. The gross proceeds to Windward from the initial public offering and the concurrent private placement (see below), without giving effect to the underwriters’ option to purchase additional shares and before deducting underwriting discounts and commissions and offering expenses, are expected to be $225.0 million. All of the common shares are being offered by Windward.

In addition to the common shares sold in the initial public offering, Windward announced a concurrent sale of 1,532,691 common shares and pre-funded warrants to purchase 1,408,485 common shares, in each case at the initial public offering price per common share, in a private placement to Sanofi Foreign Participations B.V. for an aggregate purchase price of $50.0 million. The sale of the common shares and pre-funded warrants will not be registered under the Securities Act of 1933, as amended (the “Securities Act”).

Windward’s shares are expected to begin trading on the Nasdaq Global Select Market on November 13, 2026 under the symbol “WWB.” The offering is expected to close on November 16, 2026, subject to customary closing conditions.

Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank are acting as joint book-running managers for the offering.

A registration statement relating to the shares being sold in the initial public offering has been filed with the U.S. Securities and Exchange Commission and was declared effective on November 12, 2026. The offering of the shares is being made only by means of a prospectus forming part of the effective registration statement relating to these shares. Copies of the final prospectus, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at 877-821-7388, or by email at prospectus_department@jefferies.com; TD Securities (USA) LLC, Attn: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, by telephone at (800) 747-3924, or by email at prospectus@psc.com or UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, New York 10010, by email at ol-prospectus-request@ubs.com.

The concurrent private placement is also scheduled to close on November 16, 2026, subject to the satisfaction of customary closing conditions. The closing of the private placement is contingent and conditioned on consummation of the initial public offering. However, the closing of the initial public offering is not contingent on the consummation of the concurrent private placement.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

For media and investor inquiries:
Noel Kurdi
SVP, Investor Relations and Communications
investors@windwardbio.com 


Media gallery

About The Author
Windward Bio Group AG